Daily Summary
China has banned Illumina’s DNA sequencers following new U.S. tariffs, while Medicare’s telehealth flexibilities have been extended until September 2025 to allow more types of virtual care. Meanwhile, global demand for palliative care has risen by 74% over the past 30 years, with low- and middle-income countries most affected, and the Supreme Court has ruled that the Alliance for Hippocratic Medicine lacks standing to challenge FDA regulations on mifepristone, ensuring its continued availability.
Supreme Court Rules Plaintiffs Lack Standing in FDA v. Alliance for Hippocratic Medicine
The Supreme Court ruled that the Alliance for Hippocratic Medicine lacks Article III standing to challenge FDA mifepristone regulations, reversing lower court decisions and ensuring the drug's continued availability.
Medicare Telehealth Flexibilities Extended Until September 30, 2025
Medicare telehealth flexibilities have been extended until September 30, 2025, allowing broader access to virtual care from patients' homes and other locations, though challenges in funding parity with in-person services persist.
WHO Reports 74% Global Rise in Palliative Care Demand
A recent study shows that the global need for palliative care has grown by 74% over the past three decades, driven largely by population growth and a rise in noncommunicable diseases in low- and middle-income countries.
China Bans Illumina DNA Sequencers Amid US Tariff Escalation
China has banned the import of Illumina’s DNA sequencers in retaliation to new US tariffs, following its earlier designation of the company as an 'unreliable entity.' Illumina maintains that the ban will not stop its operations in China, while it assesses the financial impact.